Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-AF03 in Patients With Malignant Solid Tumors
NCT07879547Phase 1Not yet recruiting
- Sponsor
- Yonghe Medical
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-AF03 in malignant solid tumor, sponsored by Yonghe Medical. Primary endpoints: Incidence and Severity of Adverse Events and Serious Adverse Events at 1 month, Organ Absorbed Dose of 177Lu-AF03 at 168 hours and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
177Lu-AF03
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07879547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879547.